ImmunoMatch MSI-H Predictor (Pancreatic Cancer)

ImmunoMatch MSI-H Predictor

Quickly assess the likelihood that a pancreatic tumor is MSI-H/dMMR based on available genomic and pathology data. This may help identify tumors potentially suitable for PD-1 inhibitor therapies (e.g., pembrolizumab, dostarlimab). This tool is for informational purposes ONLY and does not replace clinical diagnosis or professional medical advice.

Genomic Mutations

Check known pathogenic mutations in these genes (if tested):

MLH1 MSH2 MSH6 PMS2 POLE (pathogenic proofreading domain) POLD1 (pathogenic proofreading domain)

Mismatch Repair (MMR) Protein Immunohistochemistry (IHC)

Select the expression status for each protein (if tested):

MLH1:

MSH2:

MSH6:

PMS2:

Microsatellite Instability (MSI) PCR Testing

Select the MSI status determined by PCR (if tested):

MSI Status:

Disclaimer

This calculator provides a simplified, illustrative prediction based on limited inputs. It is NOT a substitute for professional medical advice, diagnosis, clinical testing (MSI by PCR, MMR by IHC, or Next-Generation Sequencing), or treatment decisions. The scoring algorithm is not clinically validated.

Always consult with a qualified healthcare provider and oncologist for any health concerns or before making any decisions related to your health or treatment. PD-1 inhibitor approvals and guidelines can change; refer to current FDA labeling and clinical practice guidelines (e.g., NCCN).

ImmunoMatch MSI‑H Predictor

OncoMetric Hub

ImmunoMatch MSI-H Predictor

Prediction Results

Disclaimer

ImmunoMatch MSI‑H Predictor

ImmunoMatch MSI‑H Predictor